Table 6. Literature review of chemotherapy used for HIPEC and EPIC in ovarian cancer.
| Study | Number of patients | Chemotherapy | Dose (mg/m2) |
|---|---|---|---|
| Cottee, 2007 (92) | 81 | Cisplatin | 20 mg/m2/L |
| Deraco, 2011 (93) | 26 | Cisplatin + docorubicin | 40+15 mg/L |
| Ceelen, 2009 (94) | 42 | Cisplatin or oxaliplatin | 100-250 or 460 |
| Tentes, 2012 (95) | 43 | Cisplatin + doxorubicin or gemcitabine | 50+15 or 1,000 |
| Di Giorgio, 2008 (96) | 47 | Cisplatin | 75 |
| Lim, 2009 (97) | 30 | Cisplatin | 75 |
| Pomel, 2010 (98) | 31 | Oxaliplatin | 350 or 460 |
| Roviello, 2010 (99) | 53 | Cisplatin + mitomycin C | 100+25 |
| Fagotti, 2011 (100) | 41 | Oxaliplatin | 460 |
| Helm, 2007 (101) | 18 | Cisplatin or mitomycin C | 100 or 40 |
| Lentz, 2007 (102) | 8 | Carboplatin | 400-1,200 |
| Bae, 2007 (103) | 67 | Paclitaxel or carboplatin | 175 or 350 |
| Argetna, 2013 (104) | 10 | Carboplatin | 1,000 |
HIPEC, hyperthermic intraperitoneal chemotherapy; EPIC, early post-operative intraperitoneal chemotherapy.